Literature DB >> 17097388

Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Whitney A High1, Reed A Ayers, John Chandler, Gary Zito, Shawn E Cowper.   

Abstract

BACKGROUND: Nephrogenic systemic fibrosis (NSF) is a disease of unknown etiology that affects a subset of patients with renal insufficiency. Recent publications suggested an association between exposure to gadolinium-containing contrast agents and subsequent development of NSF. We sought to detect gadolinium within the skin and soft tissue of patients with NSF who were exposed to gadolinium-based contrast.
METHODS: Paraffin-embedded skin and soft tissue from NSF patients exposed to gadolinium, and from negative controls, was provided by the NSF Registry (New Haven, Conn). The tissue was searched for metals using a field emission scanning electron microscope that was equipped with energy dispersive spectroscopy. The presence of gadolinium and other metals was verified through identification of unique and requisite X-ray emission spectra.
RESULTS: Gadolinium was detected in 4 of 13 tissue specimens from 7 patients with documented NSF who were exposed to gadolinium-based radiographic contrast. No gadolinium was detected in a paraffin-embedded specimen from a negative control. Based upon the known exposure history of patients with detectable gadolinium, a tissue residence time of 4 to 11 months was observed. LIMITATIONS: As this was a pilot investigation, only a single control specimen and a single histological section from each block of tissue were utilized.
CONCLUSION: In this pilot investigation, gadolinium was detected in the tissue of a number of patients with NSF. Although neither dispositive of a pathophysiologic mechanism, nor proof of causation, the detection of gadolinium within tissue of NSF patients is supportive of an epidemiologic association between exposure to gadolinium-containing contrast material and development of disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097388     DOI: 10.1016/j.jaad.2006.10.047

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  90 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

Review 3.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 4.  Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?

Authors:  Alexander R Rosenkranz; Thomas Grobner; Gert J Mayer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

5.  Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide.

Authors:  Tim Leiner; Christoph U Herborn; Mathias Goyen
Journal:  Eur Radiol       Date:  2007-04-26       Impact factor: 5.315

6.  [Nephrogenic systemic fibrosis. Medical detective work in the 21st century].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

7.  In Vivo Microcomputed Tomography of Nanocrystal-Doped Tissue Engineered Scaffolds.

Authors:  Stacey M Forton; Matthew T Latourette; Maciej Parys; Matti Kiupel; Dena Shahriari; Jeff S Sakamoto; Erik M Shapiro
Journal:  ACS Biomater Sci Eng       Date:  2016-02-29

8.  [Nephrogenic systemic fibrosis].

Authors:  W Samtleben
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

9.  Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.

Authors:  Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-05-09       Impact factor: 4.813

10.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.

Authors:  Josef A Schroeder; Christian Weingart; Brigitte Coras; Ingrid Hausser; Stephan Reinhold; Matthias Mack; Volker Seybold; Thomas Vogt; Bernhard Banas; Ferdinand Hofstaedter; Bernhard K Krämer
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.